AC Immune SA (ACIU) AI Stock Analysis

• Market Cap: $205.80M
• Dividend Yield: N/A
• Average Volume (3M): 120.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 95.23%
• EPS Growth: 15.55%
• Country: US
• Employees: 133
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 98,943,130
• 10 Day Avg. Volume: 118,198
• 30 Day Avg. Volume: 120,909
• PEG Ratio: 0.18
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.11
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.75
• Price Target Upside: 267.30% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 52 Neutral
• Price Target: $2.00 ▼(-5.21%Downside)

The overall score reflects a balance between potential growth and significant risks. Financial performance is hindered by persistent net losses despite revenue growth. Technical indicators show some positive momentum, but valuation concerns due to negative profitability weigh heavily on the score.

Positive Factors

Financial Health

The company ended with CHF 146M in cash, which should provide funding into 1Q27.

Partnerships

AC Immune has partnered with Dr. Klaus Gerwert’s team to exploit technology used for Alzheimer's disease to detect alpha-synuclein, which may be beneficial for measuring the efficacy of the vaccine.

Vaccine Efficacy

The development of a safe vaccine against alpha-synuclein allows potential application in preclinical or asymptomatic Parkinson’s disease patients.

Negative Factors

Market Competition

The ongoing P1b/2 ABATE study of ACI-24.060 reports promising safety profile results, which could make the approach best in class, indicating strong competition.

Price Target

The discount rate update across coverage to better reflect the current macro environment for Smid-cap biotech companies lowers the price target from $16 to $12.

AC Immune SA Business Overview & Revenue Model

Company Description

AC Immune SA (ACIU) is a Swiss-based biopharmaceutical company specializing in the development of precision medicine diagnostics and therapies for neurodegenerative diseases. The company focuses on diseases such as Alzheimer's, Parkinson's, and other related disorders, using its proprietary technology platforms to create vaccines, antibodies, and small molecules aimed at addressing these challenging medical conditions.

How the Company Makes Money

AC Immune SA generates revenue primarily through collaboration and licensing agreements with larger pharmaceutical companies. These partnerships often involve upfront payments, milestone payments upon reaching certain developmental stages, and royalties on sales of products developed through these collaborations. The company's proprietary technology platforms, such as SupraAntigen and Morphomer, are key assets that attract these alliances. Additionally, AC Immune may receive grants and funding from governmental or non-governmental organizations aimed at advancing research in neurodegenerative diseases.

AC Immune SA Financial Statement Overview

Summary

AC Immune SA shows revenue growth and improved cash flow management, but persistent net losses and profitability concerns weigh on the financial performance. The balance sheet is stable with a strong equity position, yet financial volatility presents risks.

Income Statement

The company's revenue has shown significant volatility, with revenue increasing from 2022 to 2024. However, profitability remains a concern with negative net income and EBIT margins. The gross profit margin is positive in 2024, indicating some operational efficiency improvement, but net losses persist.

Balance Sheet

AC Immune SA maintains a strong equity base relative to its assets, with a manageable debt-to-equity ratio. However, the company has been accumulating net losses, affecting its return on equity. The equity ratio is healthy, indicating stability in capital structure.

Cash Flow

The cash flow situation shows improvement with a large positive free cash flow in 2024, albeit following a negative trend in prior years. The operating cash flow to net income ratio reflects better cash management, though sustainability remains a question due to historical volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.30M	27.31M	14.80M	3.94M	0.00	15.43M
Gross Profit	11.16M	27.31M	-39.80M	-56.40M	-62.28M	-44.06M
EBITDA	-49.71M	-48.62M	-51.83M	-69.05M	-77.11M	-61.26M
Net Income	-52.08M	-50.92M	-54.23M	-70.75M	-73.00M	-62.10M
Balance Sheet
Total Assets	211.08M	230.91M	182.81M	185.94M	261.44M	238.74M
Cash, Cash Equivalents and Short-Term Investments	145.61M	165.49M	103.05M	122.59M	198.22M	225.89M
Total Debt	5.17M	5.43M	3.50M	2.80M	2.91M	2.22M
Total Liabilities	116.28M	118.64M	22.17M	16.95M	29.46M	23.26M
Stockholders Equity	94.80M	112.27M	160.64M	168.99M	231.98M	215.48M
Cash Flow
Free Cash Flow	45.31M	65.27M	-61.21M	-74.81M	-68.32M	-61.22M
Operating Cash Flow	46.00M	65.84M	-60.41M	-73.57M	-65.69M	-59.52M
Investing Cash Flow	-78.70M	-105.29M	65.64M	23.76M	-53.66M	28.33M
Financing Cash Flow	-690.00K	-1.12M	43.25M	-1.35M	40.75M	-803.00K

AC Immune SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.11
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Positive. The current price of 2.11 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 1.84, and below the 200-day MA of 2.50, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 59.22 is Neutral, neither overbought nor oversold. The STOCH value of 83.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACIU.

AC Immune SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ACIU	52 Neutral	$205.80M	―	-43.31%	―	95.23%	15.55%
Sector *	52 Neutral	$7.53B	0.20	-61.87%	2.28%	16.72%	1.10%
NBTX	51 Neutral	$260.00M	―	2152.93%	―	―	―
IKT	46 Neutral	$149.43M	―	-79.02%	―	-100.00%	38.72%
IPHA	45 Neutral	$164.84M	―	-160.99%	―	-75.67%	-552.37%
MOLN	45 Neutral	$149.74M	―	-40.40%	―	-67.23%	4.11%
SGMO	43 Neutral	$129.11M	―	-262.12%	―	239.92%	79.41%